Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

June 25, 2026 7:12 AM EDT Send to a Friend
Needham analyst Chad Messer reiterated a Buy rating and $105.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login